Opens in a new tab

Fast Growing Pharmacovigilance SaaS Leader

Fast Growing Pharmacovigilance SaaS Leader
Country
IndiaIndia
Listing ID
L#20250961
Target Price
$12,500,000
Revenue
$5,000,000
EBITDA
$2,250,000

Description

A fast-growing, cloud-native SaaS company headquartered in Bangalore with offices in the US, UK, and Europe, specializing in pharmacovigilance (PV) and clinical trial IT solutions for the global life sciences industry. The company offers an all-in-one platform combining intake, case processing, regulatory submissions, and signal detection — reducing IT costs by up to 70% and time-to-compliance by 30%.

Founded in 2017, the company has a domain-specialized team of 65+ employees based in India and supports 100+ direct clients and over 160 end clients across more than 15 countries.

Core Platform Capabilities

  • Unified PV database with AS2 Gateway

  • Web, email, and MICC intake modules

  • Case processing, auto-narratives, signal detection

  • E2B R2/R3 support and real-time analytics

  • Integrated CTMS, EDC, eTMF, ePRO, IWRS, and eConsent modules

Differentiation

  • AI-powered automations for case booking, triage, and processing

  • End-to-end unified system (vs. fragmented tools in legacy stacks)

  • Inbuilt regulatory compliance tools (e.g., submissions, reporting)

  • Trusted by top 3 of India’s top 10 pharma companies

Strategic Footprint

  • Strong presence in India, USA, UK, and broader Europe

  • Embedded in global CROs and expanding via partnerships (e.g., Wipro, Persistent, Cognizant)

  • Actively used across 250+ clinical studies

Vision

  • 2025: AI-led automation of pharmacovigilance workflows

  • 2030: Become a global top-10 PV IT provider capturing 30% market share

Basic Details

Listing ID
L#20250961
Country
India
Industry
SAAS & Software
Deal Status
Available
Target Price
$12,500,000
Revenue
$5,000,000
EBITDA
$2,250,000
Revenue Multiple
2.5x
EBITDA Multiple
5.56x

M&A Middle Market Advisory Deal Tombstones 2024

AdvisorDeals
MergersCorp M&A International21
Keith Advisory17
GCG9
JP Morgan41
Jefferies23
Lazard26
Goldman Sachs30

Businesses for Sale

Similar Opportunities